ST1535

An adenosine A2A receptor antagonist

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥2037.00

1630.00

- +
10mg

￥3475.00

2780.00

- +
25mg

￥8125.00

6500.00

- +
50mg

￥12075.00

9660.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx23520
CAS: 496955-42-1
别名:
分子式: C12H16N8
分子量: 272.3
纯度: >98%
溶解度: DMF: 5mg/mL,DMSO: 5mg/mL,DMSO:PBS (pH 7.2) (1:9): 0.1mg/mL
储存: Store at -20°C
库存: 现货

Background

ST1535 is an adenosine A_2A receptor antagonist.¹ It is selective for adenosine A_2A over A₁ receptors (K_is = 2.3 and 107 nM, respectively, in radioligand binding assays). ST1535 inhibits agonist-induced production of cAMP in CHO cells expressing adenosine A_2A receptors (IC₅₀ = 353 nM). In vivo, ST1535 (10 and 20 mg/kg) reduces haloperidol-induced catalepsy in mice. It reduces the number of jaw tremors in a rat model of Parkinsonian jaw tremors induced by tacrine .² ST1535 (20 and 40 mg/kg) increases locomotor activity and reverses motor disabilities in a marmoset model of MPTP-induced Parkinson's disease.³

1.Stasi, M.A., Borsini, F., Varani, K., et al.ST 1535: a preferential A2A adenosine receptor antagonistInt. J. Neuropsychopharmacol.9(5)575-584(2006) 2.Tronci, E., Simola, N., Borsini, F., et al.Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in ratsEur. J. Pharmacol.566(1-3)94-102(2007) 3.Rose, S., Jackson, M.J., Smith, L.A., et al.The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosetsEur. J. Pharmacol.546(1-3)82-87(2006)